Unlearn
Unlearn.ai offers an AI-powered tool known as 'Digital Twins' which aim to revolutionize clinical research. The tool offers assistance in clinical trials across...
Last verified:
What is Unlearn?
Unlearn is an AI platform for clinical development that uses digital twins, data, and AI to help trial teams make better decisions across planning, monitoring, and analysis. Its website frames the product as a
Unlearn pricing
Pricing model: Free
The website does not publish standard public pricing, free tiers, or plan levels. Instead, it repeatedly directs visitors to
Unlearn pros
- Combines planning, monitoring, and analysis in one platform
- Uses digital twins for trial participant forecasting
- Supports evidence-backed trial design decisions
- Searches scientific and regulatory precedent in one place
- Connects PubMed, ClinicalTrials.gov, and drugs@FDA sources
- Explores historical clinical and real-world datasets
- Compares endpoints, eligibility criteria, and sample size scenarios
- Makes trial-design scenarios reproducible
- Keeps assumptions, evidence, and results linked together
- Helps preserve rationale across review cycles
- Detects patient-level and site-level anomalies continuously
- Benchmarks signals against historical patient trajectories
- Supports smaller sample sizes in some randomized trials
- Can increase statistical power in trial analyses
- Aligned with EMA-qualified methodology
- Aligned with current FDA guidance
- Used by leading biopharma sponsors
- Aimed at reducing rework between clinical, stats, and regulatory teams
- Promotes faster alignment before protocol finalization
- Supports earlier go/no-go decisions
Unlearn cons
- Highly specialized for clinical development
- Not intended for non-clinical use cases
- Requires access to clinical and regulatory data
- Most useful to large sponsor organizations
- Likely needs domain expertise to interpret outputs
- May involve complex implementation across teams
- Website does not show transparent public pricing
- Not a self-serve consumer product
- Best suited to organizations running formal trials
- Digital-twin methods may not fit every study design
- Historical-data quality can affect usefulness
- Works best in supported therapeutic areas and contexts
- May require governance and regulatory review
- Not a simple point-and-click analytics app
- Could be overkill for small or early exploratory projects
Frequently asked questions about Unlearn
What does Unlearn do?
Unlearn is a clinical development platform that uses digital twins, data, and AI to help teams plan trials, monitor data, and analyze results. Its site describes the product as a way to integrate evidence, modeling, and reasoning so trial teams can make decisions with more confidence and less fragmentation.
How does Trial Planning and Simulations work?
Trial Planning and Simulations gives teams a shared workspace to search scientific and regulatory precedent, explore historical data, and build compareable trial-design scenarios. The website says teams can evaluate endpoints, eligibility criteria, sample size, and constraints while keeping assumptions and rationale linked to evidence.
What are digital twins in Unlearn’s platform?
On Unlearn’s site, digital twins are AI-generated forecasts of clinical trial participants’ expected control outcomes. They are used as external comparators in early-stage and open-label studies, and the site says they can also support smaller sample sizes or higher power in randomized trials.
Who is Unlearn for?
Unlearn is aimed at clinical development organizations, including biopharma sponsors and teams involved in trial design, statistics, operations, and governance. The website highlights use in neuroscience, immunology, metabolic disease, and other therapeutic areas.
What problems does Unlearn try to solve?
The website says clinical trials often rely on fragmented data, tools, and institutional memory, which makes high-stakes decisions harder. Unlearn tries to address that by centralizing evidence, enabling clearer scenario comparisons, detecting anomalies, and preserving decision context across review cycles.
Does Unlearn support regulatory workflows?
Yes. The site says its methodology is qualified by the EMA and aligned with current FDA guidance. It also emphasizes that its planning workflow brings in regulatory precedent and keeps evidence and assumptions transparent for review discussions.
What does the monitoring capability do?
Unlearn’s monitoring solution continuously watches for patient-level and site-level anomalies in clinical data. The site says it can flag unexpected values, off-trajectory responders, and multivariate signals using benchmarks based on historical patient trajectories rather than generic cutoffs.
What kind of evidence sources does Unlearn use?
For trial planning, Unlearn says it can search and summarize precedent from sources such as PubMed, ClinicalTrials.gov, and drugs@FDA. It also says teams can explore harmonized clinical trial and real-world datasets to validate assumptions and benchmark design choices.
Is there public pricing information?
No public pricing is shown on the website. The pages direct visitors to contact the company or schedule a demo, which indicates pricing is likely customized rather than posted as fixed subscription tiers.
What results does Unlearn claim?
The homepage highlights approximate real-world results such as 33% control arm size reduction and more than 4 months of enrollment time saved. The site presents these as approximate values and ties them to the platform’s use in clinical development.